Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Suzhou Ark Biopharmaceutical Co. Ltd. operates in the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions. These actions are distributed between 2 distinct examiners, meaning each action is handled by a different individual.
All prosecution activity is concentrated within 1 distinct art unit. OLSON, ANDREA STEFFEL is the busiest examiner, managing 1 busiest examiner pending action. This indicates that the 2 pending office actions are distributed among the 2 distinct examiners.
The fact that the workload is contained within 1 distinct art unit suggests a high degree of technical similarity in the company's current Biotechnology & Pharmaceuticals filings. However, the involvement of 2 distinct examiners means the company must navigate two different examiner perspectives within that 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681269 | COMPOUND AS ATR KINASE INHIBITOR | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681269 | COMPOUND AS ATR KINASE INHIBITOR | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719549 | CONJUGATE FOR PREVENTING AND TREATING VIRAL INFECTIONS AND USE THEREOF | OLSON, ANDREA STEFFEL | — | §102§103§112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18681269 | COMPOUND AS ATR KINASE INHIBITOR | SZNAIDMAN, MARCOS L | 1628 | §102§112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial